Anumana

What is Anumana?

Anumana develops ECG-AI algorithms that read standard electrocardiograms to detect hidden heart disease. It was founded by nference in partnership with Mayo Clinic, and its ECG-AI LEF algorithm received FDA 510(k) clearance in October 2023.

Key capabilities of Anumana

• ECG-AI LEF: detects low ejection fraction in patients at risk of heart failure
• Pulmonary hypertension: breakthrough-designated algorithm in the pipeline
• Cardiac amyloidosis: breakthrough-designated algorithm in the pipeline
• Hyperkalemia: breakthrough-designated algorithm in the pipeline
• Standard ECG input: works from ECGs already collected in care
• Clinical validation: tested in a multi-site study of 16,000 patients

How Anumana works

The algorithm analyzes a standard ECG and flags patients who may have low ejection fraction, so clinicians can follow up with confirmatory imaging. In the multi-site validation study, ECG-AI LEF reached 84.5% sensitivity and 83.6% specificity with an AUROC of 0.932. Clinicians make the diagnosis.

Who uses Anumana?

Health systems and clinicians screening patients at risk of heart failure. A Mayo Clinic trial of 22,641 adults found a 31% improvement in LEF diagnosis versus standard of care.

Anumana pricing

Anumana does not publish pricing. Quotes come from the vendor.

Anumana alternatives

Us2.ai automates echocardiogram analysis, Eko Health pairs digital stethoscopes with AI murmur and ECG detection, and Ultromics analyzes echo for heart failure. Anumana works from the ECG.